Grant: Discovery Grants Program - Individual
Queen's University
$14,000.00
Cox regression model with change-point(s) problems and their application in cancer drug development
FY 2009-10
Summary
This proposal is for developing and evaluating new statistical methods needed in cancer clinical trial practice, which will enable: 1) identifying cutoff points in predictive biomarkers or build gene signature classifier for cancer treatment selection; 2) better estimating treatment effect; 3) improved planning and analysis of clinical trials, and 4) study its implication in health economics. These methods will be implemented in the frame work of Cox regression models with change-point(s) problems.
Oncology Clinical Trials usually evaluate the efficacy of a new treatment based on population average of treatment effect . But patients are different, and most cancer treatments benefit only a minority of patients to whom they are administered, especially for targeted therapies. So it is imperative to develop effective statistical methods that can predict which patients are likely to benefit from which drug. It is hypothesized that the pretreatment gene expression profile of cancer possesses the information about the sensitivity to cancer therapy, and the information can be extracted transcriptional profiling and multigene signature predictors of response can be developed through statistical data analysis and be used for tailoring individualized treatment. The project is seeking to develop methods to determine the cutoff point(s) of a predive biomarker, find pharmacogenomic classifier using gene expression profiles as tools for treatment selection, i.e, to treat patients according to the level of the biomarker or/and the expression levels of the gene signature. Other relevant inference issues in analyzing cancer clinical trials will also be explored, such as, estimate the primary treatment effect within subgroup; health economic analysis, such as cost-effectiveness analysis.
Research topics will also be used for graduate students and post doctoral fellow training
Program
Discovery Grants Program - Individual
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data
As published
Application id
261844-2008
Name nom
Ding, Keyue
Department département
Community Health and Epidemiology
Organization id
29
Institution établissement
Queen's University
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2009
Competition year année de concours
2008
Award amount
14000
Program id
RGPIN
Program nane en
Discovery Grants Program - Individual
Program name fr
Programme de subventions à la découverte - individuelles
Group en
Discovery grants programs
Group fr
Programmes de subventions à la découverte
Committee code
14
Committee name en
Statistical Sciences
Committee name fr
Statistique
Area of application code
1205
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Mathematical sciences
Area of application fr
Sciences mathématiques
Research subject code
3005
Research subject group en
Statistics and probability
Research subject group fr
Statistique et probabilité
Research subject en
Biostatistics
Research subject fr
Biostatistiques
Partie
2
Nb partie
5
Application title
Cox regression model with change-point(s) problems and their application in cancer drug development
Keyword
NA
Application summary
This proposal is for developing and evaluating new statistical methods needed in cancer clinical trial practice, which will enable: 1) identifying cutoff points in predictive biomarkers or build gene signature classifier for cancer treatment selection; 2) better estimating treatment effect; 3) improved planning and analysis of clinical trials, and 4) study its implication in health economics. These methods will be implemented in the frame work of Cox regression models with change-point(s) problems.
Oncology Clinical Trials usually evaluate the efficacy of a new treatment based on population average of treatment effect . But patients are different, and most cancer treatments benefit only a minority of patients to whom they are administered, especially for targeted therapies. So it is imperative to develop effective statistical methods that can predict which patients are likely to benefit from which drug. It is hypothesized that the pretreatment gene expression profile of cancer possesses the information about the sensitivity to cancer therapy, and the information can be extracted transcriptional profiling and multigene signature predictors of response can be developed through statistical data analysis and be used for tailoring individualized treatment. The project is seeking to develop methods to determine the cutoff point(s) of a predive biomarker, find pharmacogenomic classifier using gene expression profiles as tools for treatment selection, i.e, to treat patients according to the level of the biomarker or/and the expression levels of the gene signature. Other relevant inference issues in analyzing cancer clinical trials will also be explored, such as, estimate the primary treatment effect within subgroup; health economic analysis, such as cost-effectiveness analysis.
Research topics will also be used for graduate students and post doctoral fellow training